Belada, D., Georgiev, P., Dakhil, S., al., e. Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma,
, .
Belada, D., Georgiev, P., Dakhil, S., al., e. .
Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
: , .
Belada, D., Georgiev, P., Dakhil, S., al., e. ()
Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma,
:
Belada, D.,
Georgiev, P.,
Dakhil, S., &
al., e.
().
Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future Oncology; Future Oncology.